Compare AstraZeneca plc (AZN) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Hut 8 Corp — how do they compare? AstraZeneca plc trades at $168.28 (market cap $253.13B), while Hut 8 Corp trades at $103.72 (market cap $11.07B). The key difference: AstraZeneca plc is far larger — about 22.9× Hut 8 Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| AZN | HUT | |
|---|---|---|
Market Cap | $253.13B | $11.07B |
Sector | Health | Technology |
52-Week High | $209.48 | $133.02 |
52-Week Low | $137.44 | $19.45 |
Enterprise Value | $279.37B | $11.33B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
HUT trades at $99.17, down 2.98% today, with a bearish technical signal. The company shows strong revenue growth potential but deep losses, with a net income margin of -109.77% in 2025. Recent news highlights its pivot to AI infrastructure, securing $16.8 billion in contracted revenue and closing a $4.25 billion investment-grade bond for data center projects.
Outlook is mixed: analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent negative cash flow from operations pose risks. The stock's near-term direction hinges on Q2 2026 earnings results and execution of its infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
